These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 25569597)

  • 1. Sirolimus Versus Tacrolimus as Primary Immunosuppressant After Renal Transplantation: A Meta-Analysis and Economics Evaluation.
    Liu JY; Song M; Guo M; Huang F; Ma BJ; Zhu L; Xu G; Li J; You RX
    Am J Ther; 2016; 23(6):e1720-e1728. PubMed ID: 25569597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tacrolimus Versus Cyclosporine as Primary Immunosuppressant After Renal Transplantation: A Meta-Analysis and Economics Evaluation.
    Liu JY; You RX; Guo M; Zeng L; Zhou P; Zhu L; Xu G; Li J; Liu D
    Am J Ther; 2016; 23(3):e810-24. PubMed ID: 25299636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the cost effectiveness of sirolimus versus tacrolimus for immunosuppression following renal transplantation in the UK.
    McEwan P; Dixon S; Baboolal K; Conway P; Currie CJ
    Pharmacoeconomics; 2006; 24(1):67-79. PubMed ID: 16445304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating the economic implications of non-adherence and antibody-mediated rejection in renal transplant recipients: the role of once-daily tacrolimus in the UK.
    Muduma G; Odeyemi I; Pollock RF
    J Med Econ; 2015; 18(12):1050-9. PubMed ID: 26201252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction with and without antithymocyte globulin combined with cyclosporine/tacrolimus-based immunosuppression in renal transplantation: a meta-analysis of randomized controlled trials.
    Tian JH; Wang X; Yang KH; Liu AP; Luo XF; Zhang J
    Transplant Proc; 2009 Nov; 41(9):3671-6. PubMed ID: 19917365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tacrolimus versus cyclosporin in renal transplantation in Italy: cost-minimisation and cost-effectiveness analyses.
    Lazzaro C; McKechnie T; McKenna M
    J Nephrol; 2002; 15(5):580-8. PubMed ID: 12455727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost effectiveness of tacrolimus versus microemulsified cyclosporin: a 10-year model of renal transplantation outcomes.
    Orme ME; Jurewicz WA; Kumar N; McKechnie TL
    Pharmacoeconomics; 2003; 21(17):1263-76. PubMed ID: 14986738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cost-utility analysis of prolonged-release tacrolimus relative to immediate-release tacrolimus and ciclosporin in liver transplant recipients in the UK.
    Muduma G; Odeyemi I; Pollock RF
    J Med Econ; 2016 Oct; 19(10):995-1002. PubMed ID: 27172118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Observations regarding the use of sirolimus and tacrolimus in high-risk cadaveric renal transplantation.
    Lo A; Egidi MF; Gaber LW; Shokouh-Amiri MH; Nazakatgoo N; Fisher JS; Gaber AO
    Clin Transplant; 2004 Feb; 18(1):53-61. PubMed ID: 15108771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A UK analysis of the cost of switching renal transplant patients from an immediate-release to a prolonged-release formulation of tacrolimus based on differences in trough concentration variability.
    Muduma G; Odeyemi I; Pollock RF
    J Med Econ; 2014 Jul; 17(7):520-6. PubMed ID: 24754700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 12-month single arm pilot study to evaluate the efficacy and safety of sirolimus in combination with tacrolimus in kidney transplant recipients at high immunologic risk.
    Lee J; Lee JJ; Kim BS; Lee JG; Huh KH; Park Y; Kim YS
    J Korean Med Sci; 2015 Jun; 30(6):682-7. PubMed ID: 26028917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
    Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative, randomized trial of concentration-controlled sirolimus combined with reduced-dose tacrolimus or standard-dose tacrolimus in renal allograft recipients.
    Bechstein WO; Paczek L; Wramner L; Squifflet JP; Zygmunt AJ;
    Transplant Proc; 2013; 45(6):2133-40. PubMed ID: 23953523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of the early conversion of tacrolimus to mammalian target of rapamycin inhibitors in patients with renal transplantation.
    Gamboa O; Montero C; Mesa L; Benavides C; Reino A; Torres RE; Castillo JS
    Transplant Proc; 2011 Nov; 43(9):3367-76. PubMed ID: 22099798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What does the CONVERT trial really tell us about conversion from calcineurin inhibitors to sirolimus?
    Hanto DW; Chudzinski R
    Transplantation; 2009 Jan; 87(2):164-5. PubMed ID: 19155968
    [No Abstract]   [Full Text] [Related]  

  • 16. Cost-effectiveness of immunosuppressive regimens in renal transplant recipients in Germany: a model approach.
    Jürgensen JS; Arns W; Hass B
    Eur J Health Econ; 2010 Feb; 11(1):15-25. PubMed ID: 19296139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
    Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of modern mTOR inhibitor based immunosuppression compared to the standard of care after renal transplantation in Germany.
    Jürgensen JS; Ikenberg R; Greiner RA; Hösel V
    Eur J Health Econ; 2015 May; 16(4):377-90. PubMed ID: 24728542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of the conversion of the immunosuppressive regimen from prograf to advagraf or to sirolimus in long-term stable liver transplant recipients: indications, safety, and outcome.
    Perrakis A; Schwarz K; Yedibela S; Croner RS; Hohenberger W; Müller V
    Transplant Proc; 2011 Dec; 43(10):3702-7. PubMed ID: 22172830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sirolimus induced dyslipidemia in tacrolimus based vs. tacrolimus free immunosuppressive regimens in renal transplant recipients.
    Hakeam HA; Al-Jedai AH; Raza SM; Hamawi K
    Ann Transplant; 2008; 13(2):46-53. PubMed ID: 18566560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.